Emile Yu and Jotin Marango

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares hit a four-month high on Wednesday following the release of strong sales by the company. HC Wainwright said underlying marketing dynamics give them confidence going forward. The firm reiterated its Buy rating and $60 price target. Analysts Andrew...